Tranche Update on Hugel, Inc.'s Equity Buyback Plan announced on February 13, 2024.
May 16, 2024 at 08:24 am
Share
From February 13, 2024 to March 31, 2024, the company has repurchased 260,000 shares, representing 2.38% for KRW 49,914.3 million. With this, the company has completed the repurchase of 260,000 shares, representing 2.38% for KRW 49,914.3 million under the buyback announced on February 13, 2024.
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.
HUGEL, INC. 
